Use of concomitant disease-modifying antirheumatic drugs (DMARD) and oral corticosteroid at commencement of infliximab and etanercept therapy.
| Infliximab, n = 38 | Etanercept, n = 75 | |||
|---|---|---|---|---|
| % | Dose*, median (range) | % | Dose*, median (range) | |
| No. DMARD (± oral corticosteroid) | ||||
| 0 | 8 | 21 | ||
| 1 | 53 | 48 | ||
| 2 | 26 | 31 | ||
| 3 | 13 | 0 | ||
| Methotrexate | 71 | 13.75 mg/wk (5–25) | 44 | 15 mg/wk (8.75–25) |
| Sulfasalazine | 26 | 2 g (1–3) | 15 | 2 g (1–3) |
| Cyclosporine | 8 | 100 (75–150) | 20 | 150 (50–350) |
| Leflunomide | 5 | 15 (10–20) | 13 | 20 (10–20) |
| Sodium aurothiomalate** | 18 | 16.7 mg/wk (10–25) | 1 | 12.5 mg/wk (range NA, n = 1) |
| Hydroxychloroquine | 8 | 300 (—) | 5 | 300 (—) |
| Podophyllotoxin derivative | 5 | 300 (—) | 8 | 300 (200–300) |
| Azathioprine | 3 | 75 (range NA, n = 1) | 1 | 100 (range NA, n = 1) |
| Auranofin | 0 | — | 1 | 6 (range NA, n = 1) |
| Oral corticosteroid | 53 | 7.5 (2.5–15) | 29 | 5 (2.5–15) |